Medical device firm Tandem Diabetes Care has received approval from the US Food and Drug Administration (FDA) for its t:slim G4 Insulin Pump, which is integrated with continuous glucose monitoring (CGM).

The approval has been granted to the pump for use by those who are 12 years of age or older and use insulin.

The firm has combined the features of t:slim Insulin Pump and Dexcom G4 Platinum CGM System in a single device that is simple to use by patients.

It conveniently shows CGM graphs and trend information with current insulin delivery activity together on the home screen, allowing patients to make informed treatment decisions.

Tandem Diabetes Care president and CEO Kim Blickenstaff said: "The t:slim G4 Pump combines our intuitive touch-screen interface and bright color display with Dexcom’s CGM technology, giving the diabetes community a powerful new tool to help simplify therapy management.

"The addition of t:slim G4 to our product family allows us to address a wider variety of diabetes management needs through the broadest range of insulin pump options available from one company."

In addition, the company produces other products such as t:slim and t:flex Insulin Pumps.